All In MedTech

Device Trial Radar · NCT07943182

Left Ventricular Impella Device Real-World Evaluation in Pediatric Patients

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 3, 2024

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Abiomed Inc.Public (JNJ)
Sponsor type
Industry
Collaborators
Johnson & Johnson
First posted
Nov 17, 2026

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, up to 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This post-approval study will evaluate the real-world safety and effectiveness of the Impella CP with SmartAssist and Impella 5.5 with SmartAssist heart pumps in pediatric patients with cardiogenic shock or severe heart failure requiring temporary mechanical circulatory support. The study will collect data from children and young adults younger than 22 years of age who receive an Impella device as part of their routine clinical care at hospitals participating in the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry. The primary objective is to assess survival at the time the Impella device is removed. Information collected during the patient's hospitalization, including clinical outcomes and adverse events, will be used to further evaluate the performance of these commercially approved devices in the pediatric population.

Conditions

  • Cardiogenic Shock
  • Heart Failure
  • Acute Decompensated Heart Failure (ADHF)
  • Cardiomyopathy
  • Myocarditis

Interventions

  • Impella CP with SmartAssistDevice

    Commercially approved temporary left ventricular support device used to provide hemodynamic support in patients requiring mechanical circulatory support.

  • Impella 5.5 with SmartAssistDevice

    Commercially approved temporary left ventricular support device used to provide hemodynamic support in patients requiring mechanical circulatory support.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival rate at Impella Device ExplantTime frame: From date of Impella implant until Impella device explant or date of death from any cause, whichever is first. The duration of time allotted until explant is not pre-specified in the study protocol but is estimated up to 12 months

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Loma Linda University Children's Hospital

    Loma Linda, California

  • Children's Hospital Los Angeles

    Los Angeles, California

21 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.